Summary:
In patients with type 2 diabetes mellitus (T2DM) following acute myocardial infarction (AMI), early administration of empagliflozin (EMPA) significantly modulated NLRP3-related inflammatory and senescence pathways in monocyte-derived macrophages compared to delayed treatment or no EMPA treatment,
though it was associated with timing-dependent anti-inflammatory effects without major adverse side effects reported in this ex-vivo analysis.
| PICO | Description |
|---|---|
| Population | Patients with type 2 diabetes mellitus (T2DM) who experienced acute myocardial infarction (AMI), with monocyte-derived macrophages isolated for ex-vivo inflammatory stimulation. |
| Intervention | Early administration of empagliflozin (EMPA) targeting NLRP3 inflammasome and senescence pathways in macrophages shortly after AMI. |
| Comparison | Delayed EMPA administration or absence of EMPA treatment, with macrophages stimulated ex-vivo under inflammatory conditions. |
| Outcome | Early EMPA treatment significantly reduced inflammatory activation and senescence markers in patient-derived macrophages compared to delayed or no treatment, suggesting timing-dependent anti-inflammatory benefits with potential to reduce residual cardiovascular risk post-AMI. |
Source: Cliff, Chelsy L., et al. “Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes.” Read article here.
